Načítá se...
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma
Multiple myeloma (MM) is a relapsed and refractory disease, one that highlights the need for developing new molecular therapies for overcoming of drug resistance. Addition of panobinostat, a histone deacetylase (HDAC) inhibitor, to bortezomib and dexamethasone improved progression-free survival (PFS...
Uloženo v:
| Vydáno v: | JCI Insight |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Clinical Investigation
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5033869/ https://ncbi.nlm.nih.gov/pubmed/27699258 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.85061 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|